10 Participants Needed

Laser Ablation for Thyroid Cancer

SS
RM
Overseen ByR. Michael Tuttle, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Percutaneous Laser Ablation (PLA) for thyroid cancer?

Research shows that Percutaneous Laser Ablation (PLA) is effective in treating various thyroid conditions, including benign thyroid nodules and papillary thyroid microcarcinoma, by reducing nodule size and treating cancerous nodules. This suggests that PLA could be a promising treatment for thyroid cancer.12345

Is laser ablation safe for thyroid conditions?

Research on percutaneous laser ablation (PLA) for thyroid conditions, including benign nodules and papillary thyroid cancer, suggests it is generally safe. Studies have evaluated its safety over several years, indicating it is a viable option for treating these conditions.15678

How is the treatment Percutaneous Laser Ablation (PLA) for thyroid cancer different from other treatments?

Percutaneous Laser Ablation (PLA) is unique because it uses laser energy to target and destroy thyroid tissue through the skin without surgery, making it less invasive than traditional surgical methods. It has been used for both benign and cancerous thyroid conditions, offering a non-surgical option for patients.12459

What is the purpose of this trial?

The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.

Research Team

RM

R. Michael Tuttle, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with a small thyroid cancer (≤13mm) called papillary thyroid microcarcinoma, who haven't spread to lymph nodes or beyond the thyroid capsule. It's for those who've declined just watching the tumor and have certain cancer cell characteristics confirmed by tests.

Inclusion Criteria

My other vocal cord works fine before the procedure.
The size of the maximum diameter of something should be 13 millimeters or less.
Your medical scans do not show any signs of cancer spreading to the lymph nodes.
See 4 more

Exclusion Criteria

My cancer has spread to my lymph nodes.
Pregnancy
Your thyroid lesion has more than 25% cysts in it.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo percutaneous laser ablation (PLA) for papillary thyroid microcarcinoma

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
Multiple visits (in-person)

Treatment Details

Interventions

  • Percutaneous Laser Ablation (PLA)
Trial Overview The study is testing percutaneous laser ablation (PLA), which uses lasers to destroy tumors without surgery, as a treatment option for removing tiny papillary thyroid cancers instead of traditional surgery.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Participants with papillary microcarcinoma (PTMC)Experimental Treatment1 Intervention
Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

References

Percutaneous laser ablation of cold benign thyroid nodules: a 3-year follow-up study in 122 patients. [2022]
Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA). [2022]
The feasibility and efficacy of ultrasound-guided percutaneous laser ablation for multifocal papillary thyroid microcarcinoma. [2022]
Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. [2022]
The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China. [2022]
[Ultrasound-guided percutaneous laser ablation for benign solid thyroid nodule: a pilot study]. [2016]
Percutaneous laser ablation for treatment of locally recurrent papillary thyroid carcinoma [2019]
Long-Term Efficacy of Ultrasound-Guided Percutaneous Laser Ablation for Low-Risk Papillary Thyroid Microcarcinoma: A 5-Year Follow-Up Study. [2022]
Percutaneous laser ablation in the treatment of toxic and pretoxic nodular goiter. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security